Gary Nachman
Stock Analyst at Raymond James
(2.90)
# 1,648
Out of 4,906 analysts
98
Total ratings
61.11%
Success rate
3.1%
Average return
Main Sectors:
Stocks Rated by Gary Nachman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABBV AbbVie | Maintains: Outperform | $220 → $227 | $184.85 | +22.80% | 15 | Apr 28, 2025 | |
| SDGR Schrödinger | Maintains: Outperform | $25 → $28 | $22.82 | +22.70% | 5 | Nov 13, 2024 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Outperform | $275 → $298 | $320.52 | -7.03% | 7 | Nov 1, 2024 | |
| LENZ LENZ Therapeutics | Initiates: Outperform | $37 | $33.58 | +10.18% | 1 | Sep 27, 2024 | |
| ACHV Achieve Life Sciences | Initiates: Strong Buy | $20 | $2.66 | +651.88% | 1 | Sep 27, 2024 | |
| PCRX Pacira BioSciences | Maintains: Outperform | $41 → $37 | $22.18 | +66.82% | 13 | Jul 31, 2024 | |
| BLCO Bausch + Lomb | Initiates: Outperform | $19 | $13.93 | +36.40% | 1 | Jul 10, 2024 | |
| AMGN Amgen | Reinstates: Market Perform | n/a | $295.87 | - | 1 | Mar 28, 2024 | |
| SRRK Scholar Rock Holding | Initiates: Strong Buy | $30 | $41.12 | -27.04% | 5 | Mar 28, 2024 | |
| AQST Aquestive Therapeutics | Initiates: Outperform | $7 | $4.23 | +65.48% | 1 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $3 | $0.58 | +417.24% | 1 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $112.65 | - | 11 | Sep 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $5 → $4 | $7.92 | -49.49% | 5 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $35 → $30 | $7.83 | +283.14% | 4 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $70 → $67 | $41.55 | +61.25% | 2 | Feb 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $32 | $5.15 | +521.36% | 1 | Feb 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $16 → $14 | $8.90 | +57.30% | 2 | Feb 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $43 → $40 | $8.97 | +345.93% | 8 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $11 → $10 | $16.31 | -38.69% | 1 | Nov 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $30 | $19.59 | +53.14% | 2 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $810 → $750 | $3.75 | +19,900.00% | 2 | Aug 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $15 → $8 | $6.32 | +26.58% | 2 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $20 → $21 | $21.18 | -0.85% | 5 | May 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $14 | $5.13 | +172.90% | 2 | Jun 14, 2018 |
AbbVie
Apr 28, 2025
Maintains: Outperform
Price Target: $220 → $227
Current: $184.85
Upside: +22.80%
Schrödinger
Nov 13, 2024
Maintains: Outperform
Price Target: $25 → $28
Current: $22.82
Upside: +22.70%
Alnylam Pharmaceuticals
Nov 1, 2024
Maintains: Outperform
Price Target: $275 → $298
Current: $320.52
Upside: -7.03%
LENZ Therapeutics
Sep 27, 2024
Initiates: Outperform
Price Target: $37
Current: $33.58
Upside: +10.18%
Achieve Life Sciences
Sep 27, 2024
Initiates: Strong Buy
Price Target: $20
Current: $2.66
Upside: +651.88%
Pacira BioSciences
Jul 31, 2024
Maintains: Outperform
Price Target: $41 → $37
Current: $22.18
Upside: +66.82%
Bausch + Lomb
Jul 10, 2024
Initiates: Outperform
Price Target: $19
Current: $13.93
Upside: +36.40%
Amgen
Mar 28, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $295.87
Upside: -
Scholar Rock Holding
Mar 28, 2024
Initiates: Strong Buy
Price Target: $30
Current: $41.12
Upside: -27.04%
Aquestive Therapeutics
Mar 28, 2024
Initiates: Outperform
Price Target: $7
Current: $4.23
Upside: +65.48%
Mar 28, 2024
Initiates: Outperform
Price Target: $3
Current: $0.58
Upside: +417.24%
Sep 29, 2023
Initiates: Market Perform
Price Target: n/a
Current: $112.65
Upside: -
Mar 3, 2023
Maintains: Market Perform
Price Target: $5 → $4
Current: $7.92
Upside: -49.49%
Mar 1, 2023
Maintains: Outperform
Price Target: $35 → $30
Current: $7.83
Upside: +283.14%
Feb 23, 2023
Maintains: Outperform
Price Target: $70 → $67
Current: $41.55
Upside: +61.25%
Feb 22, 2023
Maintains: Outperform
Price Target: $40 → $32
Current: $5.15
Upside: +521.36%
Feb 17, 2023
Downgrades: Market Perform
Price Target: $16 → $14
Current: $8.90
Upside: +57.30%
Nov 9, 2022
Maintains: Market Perform
Price Target: $43 → $40
Current: $8.97
Upside: +345.93%
Nov 7, 2022
Maintains: Market Perform
Price Target: $11 → $10
Current: $16.31
Upside: -38.69%
Nov 4, 2022
Maintains: Outperform
Price Target: $40 → $30
Current: $19.59
Upside: +53.14%
Aug 11, 2022
Maintains: Outperform
Price Target: $810 → $750
Current: $3.75
Upside: +19,900.00%
Aug 10, 2022
Maintains: Market Perform
Price Target: $15 → $8
Current: $6.32
Upside: +26.58%
May 11, 2020
Maintains: Market Perform
Price Target: $20 → $21
Current: $21.18
Upside: -0.85%
Jun 14, 2018
Maintains: Outperform
Price Target: $24 → $14
Current: $5.13
Upside: +172.90%